The establishment of new benchmarks for treatment outcomes promises to drive great advances in rheumatoid arthritis therapy, but data on 'real life' experience with biologic therapy demonstrate that geographic location influences the stage of disease at which these agents are initiated.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pease, C. et al. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. Semin. Arthritis Rheum. doi: 10.1016/j.semarthrit.2010.09.004.
Emery, P. et al. Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann. Rheum. Dis. 68, 456–459 (2009).
Breedveld, F. C. et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26–37 (2006).
Emery, P. et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe, rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372, 375–382 (2008).
Goekoop-Ruiterman, Y. P. M. et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomised trial. Ann. Intern. Med. 146, 406–415 (2007).
Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631–637 (2010).
Conaghan, P. G. et al. Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy. Rheumatology (Oxford) 49, 1894–1899 (2010).
van Vollenhoven, R. F. et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 374, 459–466 (2009).
Saleem, B. et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann. Rheum. Dis. 69, 1636–1642 (2010).
Emery, P. The Dunlop–Dottridge Lecture: prognosis in inflammatory arthritis: the value of HLA genotyping and the oncological analogy. J. Rheumatol. 24, 1436–1442 (1997).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
P. Emery has provided expert advice for and undertaken clinical trials with Abbott, BMS, Merck, Pfizer, Roche and UCB.
Rights and permissions
About this article
Cite this article
Emery, P. International disparities in access to anti-TNF therapy. Nat Rev Rheumatol 7, 197–198 (2011). https://doi.org/10.1038/nrrheum.2011.27
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2011.27
